1. Scrip
  2. >>R&D

Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well

 
• By Emily Hayes

Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.

The market for pharmaceutical-grade cannabinoid drugs is looking brighter following the success of GW Pharmaceuticals PLC in a third pivotal trial in hard-to-treat forms of epilepsy.

UK-based GW Pharmaceuticals recently announced that its cannabinoid Epidiolex – which includes cannabidiol (CBD) but not the psychoactive tetrahydrocannabinol (THC) – hit efficacy endpoints with strong statistical significance in a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

More from Scrip

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.